The autonomous communities have notified the Ministry of Health of 62,839 new cases of Covid-19 this Wednesday, after the 43,831 infections reported on Tuesday. The total number of positives now rises to 10,502,141 cases since the start of the pandemic.
The Health data for this Wednesday reflects a decrease in infections compared to the previous week, in which 86,222 positives were registered.
The accumulated incidence has been reduced by 200.83 points, standing at 1,692.52 infections per 100,000 inhabitants in the last 14 days; a reduction compared to 1,893.35 points on Tuesday.
In this Wednesday’s report, 282 new deaths have been added. Up to 95,213 people with a positive diagnostic test have died since the virus arrived in Spain, 812 in the last week.
Purchase of Novavax
The first doses of the Novavax vaccine against Covid-19 will arrive in Spain “soon”, according to the Ministry of Health in update 11 of the Vaccination Strategy.
On December 20, 2021, the European Commission authorized the Novavax vaccine, the first based on a protein platform. It thus became the fifth vaccine authorized in the European Union (EU).
The efficacy of the vaccine has been evaluated in several studies. In one of them, its efficacy against the appearance of Covid-19 from 7 days after the second dose was 90.4 percent, without any serious cases among the participants who received the vaccine.
Furthermore, no significant differences in efficacy were observed in participants at higher risk of contracting severe Covid-19 (for example, with a BMI above 30, chronic lung disease, type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease).
The results of another study show an efficacy 7 days after the administration of the second dose of 89.7 percent, with no variations depending on age (age group 18 to 64 years, the efficacy was 89.8 percent). percent and for the age group 65 to 84 years it was 88.9 percent). These studies were carried out in the periods in which the alpha variant predominated.
Taking into account the results of these clinical trials, Health proposes the use of this vaccine for people who had contraindicated the available vaccines or who have received incomplete vaccination due to serious adverse reactions to mRNA vaccines due to a history of allergy to any of its components and for other medical indications that recommend avoiding vaccination with these vaccines or other circumstances.
2022, end of Covid?
The world has the necessary resources to put an end to the Covid-19 pandemic this year, although for this it is necessary to help countries that still have problems accessing vaccines, treatments and other weapons against the coronavirus, stressed this Wednesday the secretary general of the United Nations, Antonio Guterres.
“We can end the pandemic in 2022, we are on the best path to achieve it, but we will only achieve it together,” Guterres said at an event organized by the World Health Organization (WHO) to raise more funds to help in the fight against covid-19.
Guterres affirmed that the pandemic entered its third year without yet having achieved “crucial objectives” such as the widespread vaccination of the global population, the increase in tests or the availability of all treatments capable of saving lives.
“The inequality in the distribution of vaccines is the greatest moral failure of our times, and the countries and their populations are paying for it,” assured the Portuguese politician, who stressed, however, that the distribution of doses in countries with fewer resources “is increasing exponentially.
“We can get the economy back to normal, and rescue the sustainable development goals, but we need to act now,” said the top UN official.
With today’s event, the WHO specifically requested developed countries to contribute An additional 23,000 million dollars to the global fight against the pandemicof which 16,000 million dollars will go to the ACT Accelerator and the rest will pay for the shipments of the tools against Covid-19.
This initiative was created in 2020 by the WHO and other international organizations to improve the access of developing countries to vaccines, treatments, tests and other tools against Covid-19.
With the requested money, the ACT Accelerator plans to purchase 600 million vaccines, 700 million diagnostic tests, treat 120 million patients, and provide protective equipment for 1.7 million health workers, especially in countries with larger health networks. fragile.